Elicio Therapeutics, Inc. (ELTX) – What Are Analysts Thinking About This Stock?

Shares of Elicio Therapeutics, Inc. (NASDAQ:ELTX) have earned an average rating of “Moderate Buy” from the six ratings firms that are presently covering the stock, Marketbeat Ratings reports. One analyst has rated the stock with a sell recommendation, one has given a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokers that have covered the stock in the last year is $15.00.

Several analysts have recently issued reports on ELTX shares. Wall Street Zen raised shares of Elicio Therapeutics from a “strong sell” rating to a “sell” rating in a research note on Saturday, August 15th. B. Riley Financial reduced their target price on shares of Elicio Therapeutics to $8.00 and set a “buy” rating on the stock in a report on Thursday, September 24th. HC Wainwright reissued a “buy” rating on shares of Elicio Therapeutics in a research report on Tuesday, August 18th. Finally, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Elicio Therapeutics in a research report on Tuesday, October 27th.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in ELTX. BlackRock Inc. acquired a new position in shares of Elicio Therapeutics in the 2nd quarter valued at approximately $2,995,000. Shah Capital Management acquired a new stake in Elicio Therapeutics during the third quarter valued at approximately $2,275,000. Renaissance Technologies LLC lifted its holdings in Elicio Therapeutics by 332.7% during the 1st quarter. Renaissance Technologies LLC now owns 121,631 shares of the company’s stock worth $1,300,000 after buying an additional 93,520 shares during the last quarter. Bank of America Corp DE grew its position in shares of Elicio Therapeutics by 1,225.2% in the 1st quarter. Bank of America Corp DE now owns 15,333 shares of the company’s stock worth $164,000 after acquiring an additional 14,176 shares in the last quarter. Finally, HB Wealth Management LLC acquired a new position in shares of Elicio Therapeutics in the 1st quarter worth approximately $112,000. 35.03% of the stock is owned by institutional investors and hedge funds.

Elicio Therapeutics Trading Up 7.9%

Shares of Elicio Therapeutics stock traded up $0.11 during trading hours on Friday, reaching $1.51. 756,123 shares of the company’s stock were exchanged, compared to its average volume of 285,067. The firm has a market capitalization of $40.91 million, a price-to-earnings ratio of -0.81 and a beta of 1.64. The company has a fifty day moving average of $1.91 and a 200-day moving average of $6.58. Elicio Therapeutics has a 52-week low of $1.25 and a 52-week high of $16.00. The company has a current ratio of 2.77, a quick ratio of 2.77 and a debt-to-equity ratio of 1.20.

Elicio Therapeutics (NASDAQ:ELTX) last issued its quarterly earnings results on Thursday, November 5th. The company reported ($0.30) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.44) by $0.14. Sell-side analysts forecast that Elicio Therapeutics will post -1.90 EPS for the current fiscal year.

About Elicio Therapeutics

Elicio Therapeutics, Inc (NASDAQ: ELTX) is a clinical-stage biotechnology company developing immunotherapies designed to activate the immune system against cancer. The company’s approach is based on its proprietary Amphiphile technology, which is intended to direct vaccine components and immune-stimulating agents to lymph nodes, where important immune responses are initiated.

Elicio’s lead program is ELI-002, a therapeutic cancer vaccine being developed for patients with tumors containing mutations in the KRAS gene.